Matt’s Act

Bill Number

HR 7722

Introduced

Jul 22, 2020

Latest Action

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Education and Labor, for a period ...

Sponsor

Cosponsors

Topics

Business records Congressional oversight Digestive and metabolic diseases Drug therapy Health Health care costs and insurance Health care coverage and access Inflation and prices Prescription drugs

Full Text

View Full Bill Text

Votes

Summary

Matt's Act

This bill limits the amount that private health insurance plans may charge plan holders for insulin drugs to a maximum of $20, or $0 for high deductible plans; pharmacies may charge an uninsured individual who has diabetes the average net price of such drugs after deducting any rebates and discounts provided by drug manufacturers, plus limited additional charges for distributing and dispensing costs.

Actions

Jul 22, 2020

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Education and Labor, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Jul 22, 2020

Introduced in House

Amendments

Related Bills